- Home
- BSET vs HURA Comparison
BSET vs HURA Comparison
Compare BSET & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSET
- HURA
- Stock Information
- Founded
- BSET 1902
- HURA 2009
- Country
- BSET United States
- HURA United States
- Employees
- BSET N/A
- HURA N/A
- Industry
- BSET Home Furnishings
- HURA
- Sector
- BSET Consumer Discretionary
- HURA
- Exchange
- BSET Nasdaq
- HURA Nasdaq
- Market Cap
- BSET 135.3M
- HURA 126.1M
- IPO Year
- BSET 1987
- HURA N/A
- Fundamental
- Price
- BSET $16.34
- HURA $2.48
- Analyst Decision
- BSET
- HURA Strong Buy
- Analyst Count
- BSET 0
- HURA 2
- Target Price
- BSET N/A
- HURA $11.50
- AVG Volume (30 Days)
- BSET 20.7K
- HURA 249.7K
- Earning Date
- BSET 10-08-2025
- HURA 11-13-2025
- Dividend Yield
- BSET 4.96%
- HURA N/A
- EPS Growth
- BSET N/A
- HURA N/A
- EPS
- BSET 0.28
- HURA N/A
- Revenue
- BSET $326,469,000.00
- HURA N/A
- Revenue This Year
- BSET $3.18
- HURA N/A
- Revenue Next Year
- BSET $3.84
- HURA N/A
- P/E Ratio
- BSET $57.44
- HURA N/A
- Revenue Growth
- BSET N/A
- HURA N/A
- 52 Week Low
- BSET $13.58
- HURA $1.80
- 52 Week High
- BSET $19.75
- HURA $8.40
- Technical
- Relative Strength Index (RSI)
- BSET 47.06
- HURA 44.78
- Support Level
- BSET $16.36
- HURA $2.35
- Resistance Level
- BSET $17.12
- HURA $2.64
- Average True Range (ATR)
- BSET 0.48
- HURA 0.17
- MACD
- BSET -0.02
- HURA -0.03
- Stochastic Oscillator
- BSET 28.44
- HURA 26.70
About BSET Bassett Furniture Industries Incorporated
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
About HURA TuHURA Biosciences Inc. Common Stock
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.